Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Correction: Joseph et al. Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report. Pharmaceuticals 2023, 16, 1164
Núñez, Nicolás A. , Kung, Simon , Voort, Jennifer L. Vande , Schak, Kathryn M. , Boehm, Stacey M., Carpenter, Brooke, Johnson, Emily K. , Malyshev, Grigoriy, Smits, Nathan , Adewunmi, Daniel O., Brown, Sarah K , Singh, Balwinder , Joseph, Boney , Vande Voort, Jennifer L , Singh, Balwinder , Joseph, Boney , Pazdernik, Vanessa , Smits, Nathan

Mayo Clinic

Pharmaceuticals | November 7, 2023 | Volume: 16 | Issue: 11 | Pages: 1571

10.3390/ph16111571 | PMID 38004498 Get It

In the original publication [...]
Daytime symptom trajectories among adults with stable heart failure and insomnia: evidence from a randomised controlled trial of cognitive behavioural therapy for insomnia
Conley, Samantha , Wang, Zequan , Tocchi, Christine , Linsky, Sarah , O’Connell, Meghan , Conley, Samantha , Jeon, Sangchoon , Redeker, Nancy S.

Mayo Clinic

Journal of Sleep Research | November 7, 2023 | Volume: 33 | Issue: 4 | Pages: No page available

10.1111/jsr.14058 | PMID 37933085 Get It

SummaryPeople with heart failure (HF) experience a high symptom burden and prevalent insomnia. However, little is known about daytime symptom trajectories after cognitive behavioural therapy for insomnia (CBT‐I). In this study we describe: (1) daytime symptom trajectories among adults with insomnia and stable HF over 1 year, (2) how symptom trajectories differ between CBT‐I versus HF self‐management interventions, and (3) associations between demographic, clinical, and sleep characteristics, perceived stress, health‐related quality of life (HRQoL), functional performance and daytime symptoms trajectories. We retrospectively analysed data from a randomised controlled trial of CBT‐I versus HF self‐management (NCT0266038). We measured sleep, perceived stress, HRQoL, and functional performance at baseline and symptoms at baseline, 3, 6, and 12 months. We conducted group‐based trajectory modelling, analysis of variance, chi‐square, and proportional odds models. Among 175 participants (mean [standard deviation] age 63.0 [12.9] years, 57.1% male, 76% White), we found four daytime symptom trajectories: (A) low improving symptoms (38.3%); (B) low psychological symptoms and high improving physical symptoms (22.8%); (C) high improving symptoms (24.0%); and (D) high not improving symptoms (14.9%). The CBT‐I versus the HF self‐management group had higher odds of belonging to Group A compared to other trajectories after controlling for baseline fatigue (odds ratio = 3.27, 95% confidence interval 1.39–7.68). The difference between the CBT‐I and the HF self‐management group was not statistically significant after controlling for baseline characteristics. Group D had the highest body mass index, perceived stress, and insomnia severity and the lowest cognitive ability, HRQoL, and functional performance. Research is needed to further evaluate factors contributing to symptom trajectories.
Personal Actions to Create a Culture of Inclusion: Navigating Difficult Conversations With Medical Colleagues
Sulistio, Melanie S. , Chen, Christine , Eleazu, Ijeoma , Godfrey, Sarah , Abraham, Reeni A. , Toft, Lorrel E.B., Chen, Christine L , Sulistio, Melanie S , Godfrey, Sarah

Mayo Clinic

Annals of Internal Medicine | November 6, 2023 | Volume: 176 | Issue: 11 | Pages: 1520-1525

10.7326/m23-1374 | PMID 37931258 Get It

Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials
Smith, Ashley Wilder , DiMartino, Lisa , Garcia, Sofia F. , Mitchell, Sandra A. , Ruddy, Kathryn J. , Smith, Justin D. , Cahue, September, Cella, David , Jensen, Roxanne E. , Hassett, Michael J. , Hodgdon, Christine, Richardson, Kimberly, Kroner, Barbara L, Yanez, Betina R. , Bian, Jessica , Dizon, Don S. , Hazard‐Jenkins, Hannah , Ahrens, Paige, Barrett, Fiona , Begnoche, Megan, Caron, Kimberly, Coughlin, Ava , Cronin, Christine , Dias, Samira , Farisiv, Nicolas, Flores, Anne Marie, Garcia, Martha, Kircher, Sheetal , Lancki, Nicola , Mai, Quan H, McCleary, Nadine J. , Norton, Wynne E. , O’Connor, Mary , Pachman, Deirdre R. , Pearsonil, Loretta, Podratz, Jewel, Rahman, Parvez, Redmond, Sarah , Reich, James , Schaepe, Karen , Poirier-Shelton, Tiana, Silberman, Philip , Simpson, Jaclyn, Tasker, Laura, Tesch, Nathan , Tramontano, Angela C. , Jensen, Roxanne E , Osarogiagbon, Raymond U , Cheville, Andrea L , Mitchell, Sandra A , Garcia, Sofia F , Wong, Sandra L. , Kroner, Barbara, Osarogiagbon, Raymond U. , Popovic, Jennifer R. , Schrag, Deborah , Cheville, Andrea , Kroner, Barbara L, Griffin, Joan M. , Ardini, Mary-Anne , Austin, Jessica D. , Barrett, Fiona, Bass, Michael , Chlan, Linda L. , Hemming, Karla , Herrin, Jeph , Kroenke, Kurt , Lam, Veronica, Mai, Quan H, Mallow, Jennifer A. , Penedo, Frank J. , Preiss, Liliana , Reich, James, Richardson, Joshua E. , Ridgeway, Jennifer L. , Rutten, Lila J. Finney , Scholtens, Denise M. , Tofthagen, Cindy , Tyndall, Benjamin D. , Uno, Hajime , Wehbe, Firas , Weiner, Bryan Jeffrey

Mayo Clinic

JNCI Cancer Spectrum | November 6, 2023 | Volume: 7 | Issue: 6 | Pages: No page available

10.1093/jncics/pkad073 | PMID 37930033 Get It

AbstractCancer and its treatment produce deleterious symptoms across the phases of care. Poorly controlled symptoms negatively affect quality of life and result in increased health-care needs and hospitalization. The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium was created to develop 3 large-scale, systematic symptom management systems, deployed through electronic health record platforms, and to test them in pragmatic, randomized, hybrid effectiveness and implementation trials. Here, we describe the IMPACT Consortium’s conceptual framework, its organizational components, and plans for evaluation. The study designs and lessons learned are highlighted in the context of disruptions related to the COVID-19 pandemic.
Decoding breast cancer Histopathology: Machine Learning-Enhanced Advanced Mathematical Models in Multi-B-Value MR Diffusion Imaging
Amini, Behnam, Ghasemi, Moein , Farazandeh, Dorreh, Farzaneh, Hana, Torabi, Sarah, Sedaghat, Mona, Jafarimehrabady, Niloofar, Hajiabbasi, Mobasher , Aziz, Ashkan, Gorjestani, OmidReza, Naviafar, Anahita, Alaei, Maryam , Karimi, Nastaran, Parsaei, Amirhossein , Doshmanziari, Reza, Vajihinejad, Maryam , Rikhtehgar, Masih , Nokiani, Alireza Almasi, Torabi, Sarah, Gorjestani, OmidReza, Hosseini, Mohammad M., Doshmanziari, Reza, Dehnavi, Ali Zare , Nokiani, Alireza Almasi

Mayo Clinic

No container title available | November 3, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3520062/v1 Get It

Abstract This study aims to advance breast cancer (BC) subtype classification by employing machine learning algorithms to identify key diffusion parameters from apparent diffusion coefficient (ADC0-800) histogram, intravoxel incoherent motion (IVIM), and diffusion kurtosis imaging (DKI). A total of 148 newly diagnosed BC patients were enrolled, confirmed through core needle biopsy, and subjected to histopathological analyses to assess key molecular markers such as estrogen and progesterone receptors (collectively termed hormone receptors), HER2, and ki67. These markers were then used to classify BC subtypes. Utilizing advanced post-processing techniques on multi-b-value MR Images, the study employed a diverse set of machine learning (ML) algorithms (supervised, unsupervised, and deep learning techniques) to quantitatively assess their diagnostic utility and subsequently identify algorithmically refined diffusion signatures. Machine learning algorithms demonstrated varying efficacies in the classification of BC subtypes. Key diffusion parameters were prioritized based on feature importance values from the ML models with the highest mean AUC and were further validated using group comparison tests and univariate logistic regression. In conclusion, our findings underscore the importance of tailored ML algorithms in classifying BC subtypes and advocate for a synergistic approach in personalized oncology and precision medicine.
Qualitative Assessment of Perioperative Lactation Patient Education: “I Think It's Something Women Navigate on Their Own”
Dodd, Sarah E. , Dahl, Ashley R., Sharpe, Emily E. , Warner, David O.

Mayo Clinic

Breastfeeding Medicine | November 3, 2023 | Volume: 18 | Issue: 12 | Pages: 956-959

10.1089/bfm.2023.0196 | PMID 37922459 Get It

Assessment of Sigma Error Metrics Associated with Manual Secondary Result Review and Subsequent Artificial Intelligence-Driven Quality Assurance Review—Application to Kidney Stone Analysis
Bornhorst, Joshua A. , Rokke, Denise, Day, Patrick L. , Erdahl, Sarah A , Wieczorek, Mikolaj A. , Carter, Rickey E. , Jannetto, Paul J. , Bornhorst, Joshua, Day, Patrick , Erdahl, Sarah, Carter, Rickey E , Bornhorst, Joshua

Mayo Clinic

Clinical Chemistry | November 1, 2023 | Volume: 70 | Issue: 2 | Pages: 453-455

10.1093/clinchem/hvad195 | PMID 38006322 Get It

Women 50 Years and Older With Negative Pap Test and Positive Human Papillomavirus Test for Genotypes Other Than 16 and 18—Follow-up Outcomes
Baban, Farah , Henry, Michael , Long, Margaret E. , VandeHaar, Meredith A. , Spears, Grant M. , Jenkins, Sarah M. , Salomão, Diva R.

Mayo Clinic

Journal of Lower Genital Tract Disease | October 31, 2023 | Volume: 28 | Issue: 1 | Pages: 43-47

10.1097/lgt.0000000000000772 | PMID 37906566 Get It

Objective A follow-up of women 50 years or older with concomitant positive high-risk human papillomavirus (HPV) genotypes other than 16 and 18 (hrHPVO) and negative Pap test (NILMPap) was conducted to better understand the implications of hrHPVO positivity on potential risk of developing significant high-grade lesions. Material and Methods A retrospective review of 2014 cytology data of patients with co-testing (Pap test and HPV DNA) identified 85 women 50 years or older with NILMPap and hrHPVO+. Results Most patients (63) had repeat co-testing on next follow-up. Of these, 41 patients with persistent hrHPVO+ status, 3 developed cervical intraepithelial neoplasia 2 (CIN2), and 1 CIN3. Nineteen patients were followed with biopsies. Of these, 7 biopsies were abnormal, 5 of which showed low-grade (CIN1) and 2 high-grade (CIN3) histology; none progressed on further follow-up. Three patients were followed with Pap test only, all had NILMPap, and none progressed on further follow-up. In summary, of the 85 patients, 26 developed abnormal histology during follow-up, 6 of whom had high-grade histology (CIN2 and CIN3, 3 each). The 5-year risk of CIN1+ in this cohort was 43.8% and for CIN2+ was 12.3%. The risk of abnormal histology did not differ significantly by prior history of Pap tests, histology, and/or HPV results. Conclusions A persistent positivity for hrHPVO indicated higher likelihood to develop a lesion, and this risk was not reduced for patients 50 and older compared with the published screening population risk.